Making America Healthy Again By Empowering Patients With Clear, Accurate, and Actionable Healthcare Pricing Information (Trump EO Tracker)

Authorizes the Department of War (DOW) to identify underperforming defense contractors and restrict stock buybacks, dividends, executive compensation practices, and certain advocacy benefits until contractors demonstrate sufficient performance, investment, and production capacity, using existing statutory and contractual enforcement tools when necessary.

Directs the immediate withdrawal of the U.S. from a broad set of international organizations and United Nations (UN) entities deemed contrary to U.S. interests following a comprehensive State Department review mandated by Executive Order 14199. Instructs agencies to cease participation, funding, and support for the listed organizations as soon as legally permissible, with the Secretary of State retaining authority to issue further implementation guidance and continue additional reviews.

Sets a strategy for U.S. leadership in 6G technology, emphasizing its importance for national security, AI, robotics, and resilient communications. It directs the Commerce Department’s National Telecommunications and Information Administration to “immediately begin the process of identifying” the 7.125-7.4 GHz band for “reallocation for full-powered commercial licensed use” and study how to reallocate federal systems in the band “to other frequencies” while ensuring that critical defense and electric grid missions remain unaffected. Authorizes studies to explore reallocating portions of the 2.69–2.9 GHz and 4.4–4.94 GHz bands. These efforts aim to accelerate spectrum availability for next-generation networks without compromising existing federal operations. Tasks the State Department and other agencies to lead diplomatic efforts with the ITU to advance U.S. objectives on global spectrum policy.

This order directs the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act. Schedule III drugs are classified as having a potential for abuse less than those drugs in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.